title: Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth.
abstract: Following the introduction of bulsulphan and cyclophosphamide (BUCY) conditioning in our unit in 1987, a number of patients noted incomplete scalp hair regrowth following bone marrow transplantation (BMT). Between August 1987 and May 1989, 22 patients had undergone allogeneic or autologous BMT in our unit and we recalled for detailed assessment the 14 who were alive and well at least 6 months post grafting. Six patients had experienced incomplete hair regrowth of varying severity 7-27 months following BMT. All those affected had received BUCY conditioning and the four most severely affected were allogeneic BMT recipients. No patient had received any post-BMT chemotherapy or radiation. None of the patients had evidence of graft-versus-host disease. No laboratory test abnormalities distinguished the affected from the unaffected patients. Despite the relatively small number of patients, our results suggest that BUCY has caused permanent damage to the hair follicles of the affected patients. Prolonged alopecia may markedly impair the quality of life for long-term survivors of BMT and this unexpected complication also has significant medicolegal implications.
authors.affiliation: Haematology Department, Christchurch Hospital, New Zealand.
authors.forename: B W
authors.initials: BW
authors.lastname: Baker
authors.forename: C L
authors.initials: CL
authors.lastname: Wilson
authors.forename: A L
authors.initials: AL
authors.lastname: Davis
authors.forename: R L
authors.initials: RL
authors.lastname: Spearing
authors.forename: D N
authors.initials: DN
authors.lastname: Hart
authors.forename: D C
authors.initials: DC
authors.lastname: Heaton
authors.forename: M E
authors.initials: ME
authors.lastname: Beard
mesh_terms: D000293:Adolescent; D000328:Adult; D000505:Alopecia / Q000139:chemically induced*; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D006086:Graft vs Host Disease / Q000235:genetics / Q000473:pathology; D006197:Hair / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D012535:Scalp / Q000276:immunology
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan